(Total Views: 367)
Posted On: 06/01/2020 4:33:35 PM
Post# of 36541
Another vaccine that GNBT can contribute to world health!
Ebloa Outbreak -
https://www.who.int/news-room/detail/01-06-20...e-response
An old PR from Generex on Ebola Vaccine
https://www.biospace.com/article/releases/gen...ress-inc-/
From 2/6/2020 GNBT PR -
Sometimes a small biotech company has to work harder to be noticed for their valuable work. Generex has a wealth of valuable technology that has been built with over $50 million in dollars in research and development expenditures,” said Joseph Moscato, President & CEO of Generex Biotechnology. “We had a large and successful infectious disease program a decade ago when our subsidiary NuGenerex Immuno-Oncology (then Antigen Express) was developing Ii-Key hybrid vaccines against a range of pathogens including HIV, bird flu, swine flu, Ebola , and SARS, another coronavirus.
Ebloa Outbreak -
https://www.who.int/news-room/detail/01-06-20...e-response
An old PR from Generex on Ebola Vaccine
https://www.biospace.com/article/releases/gen...ress-inc-/
From 2/6/2020 GNBT PR -
Sometimes a small biotech company has to work harder to be noticed for their valuable work. Generex has a wealth of valuable technology that has been built with over $50 million in dollars in research and development expenditures,” said Joseph Moscato, President & CEO of Generex Biotechnology. “We had a large and successful infectious disease program a decade ago when our subsidiary NuGenerex Immuno-Oncology (then Antigen Express) was developing Ii-Key hybrid vaccines against a range of pathogens including HIV, bird flu, swine flu, Ebola , and SARS, another coronavirus.
(1)
(0)Scroll down for more posts ▼
